Concomitancy and Indications for Idelalisib Use

Project Title Concomitancy and Indications for Idelalisib Use
Date Posted
Tuesday, March 13, 2018
Project ID
cder_mpl1r_wp023
Status
Complete
Deliverables
Description

This report contains estimated numbers of idelalisib users and idelalisib users with concomitant use of several anti-cancer agents as well as cancer diagnoses around the time of idelalisib use. Data from July 23, 2014 to December 31, 2015 from 15 health plans contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on May 19, 2016.

Medical Product
bendamustine
bortezomib
chlorambucil
cyclophosphamide
doxorubicin
ibritumomab
ibrutinib
idelalisib
lenalidomide
obinutuzumab
ofatumumab
prednisone
rituximab
vincristine
Population / Cohort
Individuals 18 years of age or older
Time Period
July 23, 2014 - December 31, 2015
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER